Meeting
2023 ASCO Annual Meeting
Exploring the clinical significance of specific immune-related adverse events (irAE) in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
Authors
Nethanel Asher
Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, Ramat-Gan, Israel
Nethanel Asher , Neta Bar-Hai , Ronen Stoff , Shirly Grynberg , Jacob Schachter , Ronnie Shapira-Frommer , Guy Ben-betzalel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9566)
DOI
10.1200/JCO.2023.41.16_suppl.9566
Abstract #
9566
Poster Bd #
329
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
First Author: Piyush Grover
Poster
2023 ASCO Annual Meeting
Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.
First Author: Milad Ibrahim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinical impact on treatment effectiveness of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
First Author: Keito Suzuki
Poster
2023 ASCO Annual Meeting
Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs).
First Author: Sienna Durbin